What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seropositive individuals 9-16 years of age in the first year following vaccination?

Population: 9-16 year-olds living in dengue endemic areas seropositive at vaccination

Intervention: 3 doses of CYD-TDV administered 6 months apart

Comparison: Placebo

Outcome: Virologically-confirmed dengue occurring < 25 months of completion of the first dose (13 months post dose 3)